Probi AB (publ) (“Probi”), today announced the appointment of Ole SÃ¸gaard Andersen as interim Chief Executive Officer, effective immediately. Ole SÃ¸gaard Andersen replaces CEO Peter NÃ¤hlstedt.
Ole SÃ¸gaard Andersen is an accomplished international business leader with over 30 yearsâ€™ experience in ingredients companies. He formerly held positions as President, Systems Division and Global Vice President Sales, Marketing & Application for Nutrition and Health, at DuPont. He also served on Daniscoâ€™s Board of Executives.
Probi will retain an executive search firm to recruit a new CEO to further enhance the Companyâ€™s strategies and to take Probi to its next phase of development and growth.
“We thank Peter NÃ¤hlstedt for his achievements in developing Probi into a leading global probiotics company and for his dedicated service to the company. Probi is already in a good position to carry on with its growth strategy. I am convinced that Ole SÃ¸gaard Andersen will fully utilise the growth opportunities in the market, until a new permanent CEO has been appointed”, said Jean-Yves Parisot, Chairman of the Board.
This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 14 March 2018 at 15.50pm CET.
FOR FURTHER INFORMATION, CONTACT:
Jean-Yves Parisot, Chairman of the Board, Probi, tel +33 670 48 0684, e-mail: [email protected]
Niklas Brandt, CIO & Investor Relations, Probi, tel +46 46 286 89 26, e-mail: [email protected]
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.com.
Latest posts by Jasmine Petters (see all)
- Research Details Developments in the Medical Device Technologies Market on Global Market Will Make a Huge Impact in Near Future - March 20, 2018
- Statement by Kelly M. Semrau, Senior Vice President Global Corporate Affairs, Communication and Sustainability at SC Johnson - March 20, 2018
- Animal Antibiotics Market Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Fluoroquinolone) Worth +4 Billion USD by 2021 - March 20, 2018